Last updated: February 21, 2026
Palbociclib is an oral CDK4/6 inhibitor used primarily for hormone receptor-positive, HER2-negative breast cancer. Several companies manufacture and supply palbociclib, either through proprietary production or licensing agreements.
Manufacturing Companies and Licensed Suppliers
1. Pfizer Inc.
- Role: Original developer and patent holder.
- Product: Ibrance (brand name for palbociclib).
- Manufacturing: Pfizer manufactures and supplies palbociclib globally, including key markets like the U.S., Europe, and Asia.
- Regulatory Status: Approved in multiple jurisdictions; manufacturing complies with cGMP standards.
2. Authorized Generic and Biosimilar Suppliers
- Sandoz (Novartis division): Engages in biosimilar and generic production of cancer drugs, potentially including palbociclib via licensing or partnerships.
- Mylan (now part of Viatris): Has capacity for generic oncology drugs, but specific production of palbociclib remains unconfirmed.
- Sun Pharmaceutical Industries: Has announced plans to produce generic cancer medications but no explicit confirmation on palbociclib.
3. Contract Manufacturing Organizations (CMOs)
- CordenPharma: Offers development and manufacturing services for APIs, including those in oncology.
- Patheon (Thermo Fisher Scientific): Provides CDMO services for complex molecules, including potential API production of palbociclib.
- Samsung Biologics: Focus on biologics, with limited involvement in small molecule APIs like palbociclib.
Supply Chain and Distribution Factories
- Pfizer's global supply chain includes manufacturing sites in the US, Europe, and Asia.
- Key European manufacturing facilities are located in Belgium and Germany.
- Asian production is located in India and China, primarily for regional supply.
Regulatory and Patent Timeline
- Patent Expiry: Expected around 2028 in the US, after which generics are likely to enter the market.
- Regulatory Approvals: FDA (2015), EMA (2016), and other regulators approved palbociclib for metastatic breast cancer.
- Compulsory Licensing and Patent Challenges: Not yet reported for palbociclib; potential generic entry post-2028.
Market Dynamics
- Market Leaders: Pfizer dominates sales under the brand Ibrance.
- Generic Competition: Expected to increase post-patent expiry, with several Indian manufacturers preparing for entry.
- Pricing and Supply: Pfizer's pricing varies by region; generics are expected to reduce costs significantly.
Summary Table: Key Suppliers and Roles
| Company |
Role |
Market Presence |
Manufacturing Sites |
| Pfizer Inc. |
Original Patent Holder & Manufacturer |
Global (US, Europe, Asia) |
US, Belgium, Germany |
| Sandoz (Viatris) |
Biosimilars/Generics |
Europe, US |
US, Switzerland |
| Mylan |
Generics (Potential) |
Global |
India, Europe |
| Sun Pharma |
Generics (Potential) |
India, emerging markets |
India |
| CordenPharma |
API Contract Manufacturing |
Europe, US |
Germany, US |
| Patheon (Thermo Fisher) |
API Contract Manufacturing |
US, Europe |
US, Netherlands |
Key Takeaways
- Pfizer is the primary supplier of palbociclib globally under Ibrance.
- Generic manufacturers in India and China are preparing for market entry after patent expiration around 2028.
- Contract manufacturing organizations provide API production services, with limited direct involvement in branded supply.
- The supply chain spans multiple regions, with manufacturing hubs in North America, Europe, and Asia.
- The competitive landscape is set to change significantly once patent protections lapse, increasing supply options and reducing prices.
FAQs
1. Who manufactures palbociclib?
Pfizer manufactures palbociclib under the brand Ibrance; other companies produce generics post-patent expiry.
2. Are there biosimilar options for palbociclib?
Currently, biosimilar options are limited since palbociclib is a small molecule, not a biologic. Manufacturers may develop generic versions, especially after patent expiry.
3. Which companies supply API for palbociclib?
CordenPharma and Patheon offer API manufacturing services for small molecules, including potential production for palbociclib.
4. When will generic palbociclib enter the market?
Post-2028, after Pfizer's patent expiration in key markets like the US.
5. Can regional manufacturers supply palbociclib?
Yes, intra-regional manufacturers in India and China are preparing for generic entry, potentially providing supply at lower costs.
References
[1] Pfizer Inc. (2022). Ibrance (palbociclib) prescribing information.
[2] European Medicines Agency. (2016). Ibrance approval details.
[3] U.S. Food & Drug Administration. (2015). Palbociclib approval letter.
[4] GlobalData. (2023). Oncology API manufacturing market overview.
[5] Statista. (2023). Oncology drug market and generic competition analysis.
